Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of 'Knock-Out' ...(methods for the specific targeted disrup...),Health

Date:3/24/2008

methods for the specific, targeted disruption of any gene. Our ZFN technology facilitates this in a rapid, single-step process. Importantly, the process enables the simultaneous disruption of both cellular copies of the gene of interest with an efficiency that obviates the need for selection markers and other complicated strategies to identify knockout cells -- a dramatic improvement over existing methodologies."

The work, co-authored by scientists at Sangamo and Pfizer Inc, was published online on March 21, 2008, http://www.pnas.org/cgi/content/abstract/0800940105v1 in the Early Edition of the Proceedings of the National Academy of Sciences ("Targeted Gene Knockout in Mammalian Cells Using Engineered Zinc Finger Nucleases").

The data demonstrate that ZFN technology can be used to significantly speed up the process of generating cell lines in which a single gene is specifically knocked out. ZFNs were used to place a double strand break in the DNA sequence precisely within the gene to be eliminated. The process then takes advantage of the cell's DNA repair system which repairs the break in the sequence. This natural process often results in a small amount of DNA being deleted at the site of the break and the consequent disruption of the expression of the gene and the protein that it encodes. Sangamo and Pfizer scientists demonstrated that the disruption process occurred with sufficiently high frequency that selection markers were not required to identify multiple independent knockout cell lines with minimal screening effort.

"This publication represents ground-breaking work in the use of ZFNs and highlights an application of this powerful technology that is expected to revolutionize research, drug development, and protein production. Sigma's aim is to make the technology widely available to scientists throughout the world," stated David Smoller, Ph.D., President of
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
9. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
10. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
11. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout